gatifloxacin has been researched along with Keratitis, Ulcerative in 25 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 7.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 3.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "The developed system is a viable alternative to conventional eyedrops of GTN due to its ability to enhance bioavailability through its longer precorneal residence time." | 1.43 | Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel. ( Kant, S; Kesavan, K; Pandit, JK, 2016) |
| "Besifloxacin-treated eyes had significantly lower CFU recovered as compared with that of gatifloxacin- and moxifloxacin-treated eyes (P < 0." | 1.37 | Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. ( Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2011) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin, and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea." | 1.36 | Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2010) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection." | 1.35 | Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2009) |
| "Use the ID(50) (infectious dose to 50% of experimental animals) to quantify the most effective prophylactic dosing regimen to use with gatifloxacin 0." | 1.34 | Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. ( Friday, JW; Kleinert, LB; Nix, DE; Patula, VB; Slade, DS; Snyder, RW, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, A | 1 |
| Li, S | 1 |
| Ruan, F | 1 |
| Jie, Y | 1 |
| Suzuki, T | 1 |
| Ohashi, Y | 1 |
| Kaliamurthy, J | 2 |
| Kalavathy, CM | 2 |
| Parmar, P | 2 |
| Nelson Jesudasan, CA | 1 |
| Thomas, PA | 2 |
| Kesavan, K | 1 |
| Kant, S | 1 |
| Pandit, JK | 1 |
| Betanzos-Cabrera, G | 1 |
| Juárez-Verdayes, MA | 1 |
| González-González, G | 1 |
| Cancino-Díaz, ME | 1 |
| Cancino-Díaz, JC | 1 |
| Sanders, ME | 3 |
| Norcross, EW | 3 |
| Moore, QC | 3 |
| Shafiee, A | 3 |
| Marquart, ME | 3 |
| Lekhanont, K | 1 |
| Chuckpaiwong, V | 1 |
| Chongtrakool, P | 1 |
| Aroonroch, R | 1 |
| Vongthongsri, A | 1 |
| Perez-Balbuena, AL | 1 |
| Vanzzini-Zago, V | 1 |
| Garza, M | 1 |
| Cancino, DC | 1 |
| Shah, VM | 1 |
| Tandon, R | 2 |
| Satpathy, G | 1 |
| Nayak, N | 1 |
| Chawla, B | 2 |
| Agarwal, T | 1 |
| Sharma, N | 1 |
| Titiyal, JS | 2 |
| Vajpayee, RB | 1 |
| Sanfilippo, CM | 1 |
| Hesje, CK | 1 |
| Blair, J | 1 |
| Hodge, W | 1 |
| Al-Ghamdi, S | 1 |
| Balabanian, R | 1 |
| Lowcock, B | 1 |
| Pan, YI | 1 |
| Sherif, H | 1 |
| AlMahmoud, T | 1 |
| Fergusson, D | 1 |
| Slomovic, A | 1 |
| Kowalski, RP | 3 |
| Dhaliwal, DK | 1 |
| Karenchak, LM | 1 |
| Romanowski, EG | 3 |
| Mah, FS | 3 |
| Ritterband, DC | 1 |
| Gordon, YJ | 3 |
| Hyon, JY | 1 |
| Joo, MJ | 1 |
| Hose, S | 1 |
| Sinha, D | 1 |
| Dick, JD | 1 |
| O'Brien, TP | 1 |
| Jensen, H | 1 |
| Zerouala, C | 1 |
| Carrier, M | 1 |
| Short, B | 1 |
| Yates, KA | 2 |
| Salman, A | 1 |
| Prasanth, DA | 1 |
| Jesudasan, CA | 1 |
| Moshirfar, M | 2 |
| Mirzaian, G | 1 |
| Feiz, V | 1 |
| Kang, PC | 1 |
| Mehta, S | 2 |
| Jiandani, P | 1 |
| Slade, DS | 1 |
| Friday, JW | 1 |
| Snyder, RW | 1 |
| Nix, DE | 1 |
| Kleinert, LB | 1 |
| Patula, VB | 1 |
| Mamalis, N | 1 |
| Meyer, JJ | 1 |
| Espandar, L | 1 |
| Agarwal, P | 1 |
| Balzli, CL | 1 |
| McCormick, CC | 1 |
| Caballero, AR | 1 |
| Huang, B | 1 |
| Wigington, L | 1 |
| Smith, E | 1 |
| Tang, A | 1 |
| O'Callaghan, RJ | 1 |
3 trials available for gatifloxacin and Keratitis, Ulcerative
| Article | Year |
|---|---|
Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefazolin; Child; Corneal U | 2010 |
Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Corneal Ulcer; Dexamethasone; Double-Blind Method; Drug Ther | 2011 |
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Child; Ciprofloxacin; | 2006 |
22 other studies available for gatifloxacin and Keratitis, Ulcerative
| Article | Year |
|---|---|
Atopic keratoconjunctivitis: A diagnostic dilemma-a case report.
Topics: Administration, Topical; Adolescent; Anti-Allergic Agents; Anti-Bacterial Agents; Conjunctivitis, Al | 2018 |
Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefmenoxime; Corneal Ulcer; Drug Combinations; Drug | 2013 |
Spectrum of bacterial keratitis at a tertiary eye care centre in India.
Topics: Aza Compounds; Ciprofloxacin; Corneal Ulcer; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; | 2013 |
Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel.
Topics: Alginates; Animals; Anti-Bacterial Agents; Biological Availability; Carboxymethylcellulose Sodium; C | 2016 |
Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.
Topics: Anti-Infective Agents; Aza Compounds; Conjunctivitis; Corneal Ulcer; DNA Gyrase; DNA Topoisomerase I | 2009 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2009 |
Pythium insidiosum keratitis in contact lens wear: a case report.
Topics: Anti-Infective Agents; Contact Lenses, Hydrophilic; Corneal Ulcer; Disposable Equipment; Drug Admini | 2009 |
Atypical mycobacterium keratitis associated with penetrating keratoplasty: case report of successful therapy with topical gatifloxacin 0.3%.
Topics: Administration, Topical; Anti-Infective Agents; Corneal Ulcer; Eye Infections, Bacterial; Fluoroquin | 2010 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2010 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2011 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacte | 2003 |
Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Co | 2004 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disea | 2005 |
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefazolin; Corneal Ulcer; Disease Mode | 2005 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Com | 2006 |
Ocular features of dengue septic shock (DSS).
Topics: Adult; Anti-Infective Agents; Corneal Ulcer; Dengue; Female; Fluoroquinolones; Gatifloxacin; Humans; | 2006 |
Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Colony Count, Microbial; Corneal Ulcer; Dise | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Model | 2007 |
The increasing problem of antibiotic resistance.
Topics: Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Drug Resistance, Bacterial; Eye Infections, Bac | 2007 |
Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Topics: Adult; Amikacin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Doxycycline; D | 2007 |
Peripheral ulcerative keratitis with bilateral optic nerve involvement as an initial presentation of acute lymphocytic leukemia in an adult.
Topics: Adult; Corneal Ulcer; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Int | 2009 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulce | 2008 |